Oral vaccines: New needs, new possibilities

BioEssays

Volumn 29, Issue 6, 2007, Pages 591-604

  Aziz, Mohd Azhar ^a   Midha, Shuchi ^c   Waheed, Syed Mohsin ^b   Bhatnagar, Rakesh ^c  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c JAWAHARLAL NEHRU UNIVERSITY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; BACTERIAL VACCINE; BCG VACCINE; CANCER VACCINE; CHITOSAN; CHOLERA VACCINE; ENVELOPE PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIPOSOME; MALARIA VACCINE; MEASLES VACCINE; MEMBRANE PROTEIN; MUTANT PROTEIN; NUCLEOCAPSID PROTEIN; POLIOMYELITIS VACCINE; PROTEIN VP7; PROTOZOAL PROTEIN; PROTOZOAL VACCINE; RECOMBINANT VACCINE; SALMONELLOSIS VACCINE; SAPONIN DERIVATIVE; SURFACE PROTEIN 1; SURFACE PROTEIN CS6; UNCLASSIFIED DRUG; VACCINE; VIRUS PROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTHRAX; ARTICLE; CHOLERA; DIARRHEA; DRUG DELIVERY SYSTEM; GASTROENTERITIS; HOST RESISTANCE; HUMAN; IMMUNE RESPONSE; IMMUNITY; MALARIA; MEASLES; MOUTH MUCOSA; ORAL DRUG ADMINISTRATION; TUBERCULOSIS; UTERINE CERVIX CANCER; VACCINATION;

ADMINISTRATION, ORAL; COMMUNICABLE DISEASES; DEVELOPING COUNTRIES; HEALTH SERVICES NEEDS AND DEMAND; HUMANS; IMMUNITY, MUCOSAL; IMMUNIZATION PROGRAMS; VACCINATION; VACCINES; WORLD HEALTH;

EID: 34250175071     PISSN: 02659247     EISSN: None     Source Type: Journal    
DOI: 10.1002/bies.20580     Document Type: Article

References (128)

1. Morens DM, Folfers GK, Fauci AS. 2004. The challenge of emerging and re-emerging infectious diseases. Nature 430:242-249.
2. Berzofsky JA, Ahlers JD, Janik J, Morris J, Oh S, et al. 2004. Progress on new vaccine strategies against chronic viral infections. J Clin Invest 114: 450-462.
3. Henderson DA. 1998. Eradication: Lessons from the past. Bulletin- World Health Organization 76:17-21.
4. Institute of Medicine. 1986. New vaccine development: establishing Priorities. Volume II, Diseases in Developing countries. Washington, DC: National Academy Press. pp. 1-16.
5. Holmgren J, Czerinsky C. 2005. Mucosal immunity and vaccines. Nat Medicine Supplement 11:545-553.
6. World health Organization: The world Health report. 2004. (World health Organization), Geneve, 2004.
7. Levine MM. 2003. Can needle-free administration of vaccines become the norm in global immunization? Nat Med 9:99-103.
8. Mastroeni P, Bowe F, Cahill R, Simmons C, Dougan G. 1999. Vaccines against gut pathogens. Gut 45:633-635.
9. Bouvet JP, Decroix N, Pamonsinlapatham P. 2002. Stimulation of local antibody production: parenteral or mucosal vaccination? Trends Immunol 23:209-213.
10. Mowat AM. 2003. Anatomical basis of tolerance and immunity to intestinal antigens. Nat Rev Immunol 3:331-341.
11. Kunkel D, Kirchoff D, Nishikawa S, Radbruch A, Scheffold A. 2003. Visualisation of peptide presentation following oral application of antigen in normal and Peyer's patches-deficient mice. Eur J Immunol 33:1292-1301.
12. Bland PW, Warren LG. 1986. Antigen presentation by epithelial cells of rat small intestine. I. Kinetics, antigen specificity and blocking by anti-Ia sera. Immunology 58:1-7.
13. Bland PW, Warren LG. 1986. Antigen presentation by epithelial cells of rat small intestine. II. Selective induction of suppressor T-cells. Immunology 58:1-7.
14. Kerneis S, Bogdanova A, Kaehenbuhl JP, Pringault E. 1998. Conversion by Peyer's patches lymphocytes into M cells that transport bacteria. Science 277:949-952.
15. Smith MW, James PS, Tivey DR. 1987. M cell numbers increase after transfer of SPF mice to a normal animal house environment. Am J Pathol 128:385-389.
16. Savidge TC, Smith MW, James PS, Aldred P. 1991. Salmonella-induced M-cell formation in germ-free mouse Peyer's patch tissue. Am J Pathol 139:177-184.
17. Jepson MA, Clark MA, Foster N, Mason CM, Bennett MK, et al. 1996. Targeting to intestinal M cells. J Anat 189:507-516.
18. Neutra MR, Phillips T, Mayer E, Fishkind DJ. 1987. Transport of membrane bound macromolecules by M cells in follicle associated epithelium of rabbit Peyer's patch. Cell Tissue Res 247:537-546.
19. Owen RL. 1977. Sequential uptake of horseradish peroxidase by lymphoid follicle epithelium of Peyer's patches in the normal unobstructed mouse intestine: an ultrastructural study. Gastroenterology 72:440-451.
20. Maric I, Holt PG, Perdue MH, Bienenstock J. 1996. Class II MHC antigen (Ia)-bearing dendritic cells in the epithelium of the rat intestine. J Immunol 156:1408-1414.
21. Kelsall B, Strober W. 1996. Distinct populations of dendritic cells are present in the subepithelial dome and T cell recognition regions of the murine Peyer's patch. J Exp Med 183:237-247.
22. Iwasaki A, Kelsall BL. 2001. Unique functions of CD11b+, CD8 alpha+, and double-negative Peyer's patch dendritic cells. J Immunol 166(8): 4884-4890.
23. Yuki Y, Kiyono H. 2003. New generation of mucosal adjuvants for the induction of protective immunity. Rev Med Virol 13:293-310.
24. Sato A, Iwasaki A. 2005. Peyer's patch dendritic cells as regulators of mucosal adaptive immunity. Cell Mol Life Sci 62:1333-1338.
25. London SD, Rubin DH, Cebra JJ. 1987. Gut mucosal immunization with reovirus serotype 1/L stimulates virus-specific cytotoxic T cell precursors as memory cells in Peyer's patches. J Exp Med 165:830-847.
26. Kantele A, Zivny J, Hakkinen M, Elson CO, Mestecky J. 1999. Differential homing commitments of antigen-specific T cells after oral or parentral immunization in humans. J Immunol 162:5173-5177.
27. 7 integrin mediates lymphocyte binding to the mucosal vascular addressin MADCAM-1. Cell 74:185-195.
28. Butcher EC, Williams M, Youngman K, Rott L, Briskin M. 1999. Lymphocyte trafficking and regional immunity. Adv Immunol 72:209-253.
29. Yoshida H, Naito A, Inoue J, Satoh M, Santee-Cooper SM, et al. 2002. Different cytokines induce surface lymphotoxin-αβ on IL-7 receptor-α cells that differentially engender lymph nodes and Peyer's patches. Immunity 17:823-833.
30. Bowman EP, Kuklin NA, Youngman KR, Lazarus NH, Kunkel EJ, et al. 2002. The intestinal chemokine thymus- expressed chemokine (CCL25) attracts IgA antibody secreting cells. J Exp Med 195:269-275.
31. Hamann A, Andrew DP, Jablonski-Westrich D, Holzmann B, Butcher EC. 1994. Role of alpa 4-integrinsin lymphocyte homing to mucosal tissues in vivo. J Immunol 152:3282-3293.
32. Svensson M, Marsal J, Ericsson A, Carramolino L, Broden T, et al. 2002. CCL25 mediates the localization of recently activated CD8 alpha beta (+) lymphocytes to thesmall-intestinal mucosa. J Clin Invest 110:1113-1121.
33. Mora JR, Bono MR, Manjunath N, Weninger W, Cavanagh LL, et al. 2003. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 424:88-93.
34. Johansson-Lindbom B, Svensson M, Wurbel MA, Malissen B, Marquez G, et al. 2003. Selective generation of gut tropic T cells in gut-associated lymphoid tissue (GALT): requirement for GALT dendritic cells and adjuvant. J Exp Med 198:963-969.
35. Stagg AJ, Kamm MA, Knight SC. 2002. Intestinal dendritic cells increase T cell expression of alpha4beta7 integrin. Eur J Immunol 32:1445-1454.
36. Williams IR. 2004. Chemokine receptors and leukocyte trafficking in the mucosal immune system. Immunol Res 29:283-292.
37. Campbell DJ, Butcher EC. 2002. Rapid acquisition of tissue-specific homing phenotypes by CD4+ T-cells activated in cutaneous and mucosal lymphoid tissues. J Exp Med 195:135-141.
38. Sonoda E, Matsumoto R, Hitoshi Y, Ishii T, Sugimoto M, et al. 1989. Transforming growth factor beta induces IgA production and acts additivety with interleukin 5 for IgA production. J Exp Med 170:1415-1420.
39. Lebman DA, Nomura DY, Coffman RL, Lee FD. 1990. Molecular characterization of germ line immunoglobulin A transcripts produced during transforming growth factor type β-induced isotype switching. Proc Natl Acad Sci USA 87:3962-3966.
40. Coffman RL, Seymour BWP, Lebman DA, Hiraki DD, Christiansen JA, et al. 1988. The role of helper T-cell products in mouse B-cell differentiation and isotype regulation. Immunol Rev 102:5-28.
41. Iijima H, Takahashi I, Kiyono H. 2001. Mucosal immune network in the gut for the control of infectious diseases. Rev Med Virol 11:117-133 and references therein
42. Verdonck F, Cox E, Goddeeris BM. 2004. F4 fimbriae expressed by porcine enterotoxigenic Escherichia coli, an example of an eccentric fimbrial system. J Mol Microbiol Biotechnol 7:155-169.
43. Pasetti MF, Levine MM, Sztein MB, 2003. Animal models paving the way for clinical trials of attenuated Salmonella enterica serovar Typhi live oral vaccines and live vectors. Vaccine 21:401-418.
44. Eo SK, Yoon HA, Aleyas AG, Park SO, Han YW, et al. 2006. Systemic and mucosal immunity induced by oral somatic transgene vaccination against glycoprotein B of pseudorabies virus using live attenuated Salmonella typhimurium. FEMS Immunol Med Microbiol 47:451-461.
45. Weidig CA, Kramer U, Garbom S, Wolf-Watz H, Autenrieth IB, et al. 2005. Induction of CD8+ T cell responses by Yersinia vaccine carrier strains. Vaccine 23:4984-4998.
46. Seegers JF. 2002. Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends in Biotech 20:505-515.
47. Locht C. 2000. Live bacterial vectors for intranasal delivery of protective antigens. Pharm Sci Technol Today 3:121-128.
48. Ball JM, Graham DY, Opekun AR, Gilger MA, Guerrero RA, et al. 1999. Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology 117:255-257.
49. Eriksson K, Holmgren J. 2002. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 14:666-672.
50. Shi W, Liu J, Huang Y, Qiao L. 2001. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol 75:10139-10148.
51. Morris W, Steinhoff MC, Russell PK. 1994. Potential of polymer microencapsulation technology for vaccine innovation. Vaccine 12: 5-11.
52. Michalek SM, Eldridge JH, Curtiss R III, Rosenthal KL. 1994. Antigen delivery systems: new approaches to mucosal immunization. In: Ogra PL, Mestecky J, Lamm ME, Strober W, McGhee JR, Bienenstock J, editors. Handbook of Mucosal Immunology. Boston: Academic Press, Inc. pp. 373-380.
53. Shalaby W. 1995. Development of oral vaccines to stimulate mucosal and systemic immunity: barriers and novel strategies. Clin Immunol Immunopathol 74:127-134.
54. Katz DE, DeLorimier AJ, Wolf MK, Hall ER, Cassels FJ, et al. 2003. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 21:341-346.
55. Marx PA, Compans RW, Gettie A, Staas JK, Gilley RM, et al. 1993. Protection against SIV vaginal transmission with microencapsulated vaccine. Science 260:1323-1327.
56. Zho F, Neutra MR. 2002. Antigen delivery to mucosa-associated lymphoid tissues using liposomes as a carrier. Biosci Rep 22:355-369.
57. Van der Lubben IM, Verhoef JC, Borchard G, Junginger HE. 2001. Chitosan and its derivatives in mucosal drug and vaccine delivery. Eur J Pharm Sci 14:201-207.
58. Van der Lubben IM, Verhoef JC, van Aelst AC, Borchard G, Junginger HE. 2001. Chitosan microparticles for oral vaccination: preparation, characterization and preliminary in vivo uptake studies in murine Peyer's patches. Biomaterials 22:687-694.
59. Singh M, O'Hagan D. 1999. Advances in vaccine adjuvants. Nature Biotech 17:1075-1081.
60. Kirk DD, Rempel R, Pinkhasov J, Walmsley AM. 2004. Application of Quillaja saponaria extracts as oral adjuvants for plant-made vaccines. Expert Opin Biol Ther 4:947-958.
61. Kensil CR. 1996. Saponins as vaccine adjuvants. Crit Rev Ther Drug Carrier Syst 13:1-55.
62. Pickering RJ, Smith SD, Strugnell RA, Wesselingh SL, Webster DE. 2006. Crude saponins improve the immune response to an oral plant-made measles vaccine. Vaccine 24:144-150.
63. Tacket CO, Mason HS, Losonsky G, Clements JD, Levine MM, et al. 1998. Immunogenicity in humans of a recombinant bacterial antigen delivered in transgenic potato. Nat Med 4:607-609.
64. Aziz MA, Singh S, Anand Kumar P, Bhatnagar R. 2002. Expression of protective antigen in transgenic plants: a step towards edible vaccine against anthrax. Biochem Biophy Res Commun 299:345-351.
65. Kusnadi AR, Evangelista RL, Hood EE, Howard JA, Nikolov ZL. 1998. Processing of transgenic corn seed and its effect on the recovery of recombinant beta-glucuronidase. Biotechnol Bioeng 60:44-52.
66. Hood EE, Jilka JM. 1999. Plant-based production of xenogenic proteins. Curr Opin Biotechnol 10:382-386.
67. Staub JM, Garcia B, Graves J, Hajdukiewicz PT, Hunter P, et al. 2000. High-yield production of a human therapeutic protein in tobacco chloroplasts. Nat Biotechnol 18:333-337.
68. Korban SS, Krasnyanski SF, Buetow DE. 2002. Foods as production and delivery vehicles for human vaccines. J Am Coll Nutr 21:212S-217S.
69. Daniell H, Dhingra A. 2002. Multigene engineering: dawn of an exciting era in biotechnology. Curr Opin Biotechnol 13:136-141.
70. Maliga P. 2002. Engineering the plastid genome of higher plants. Curr Opin Plant Biol 5:164-172.
71. Clements JD, Hartzog NM, Lyon FL. 1988. Adjuvant activity of Escherichia coli heat-labile enterotoxin and effect on the induction of oral tolerance in mice to unrelated protein antigens. Vaccine 6:269-277.
72. Svenerholm J. 1976. Interaction of cholera toxin and ganglioside G (M1). Adv Exp Med Biol 71:191-204.
73. Hajishengallis G, Hollingshead SK, Koga T, Russell MW. 1995. Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J Immunol 154:4322-4332.
74. Holmgren J, Lycke N, Czerkinskey C. 1993. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine 12:1179-1184.
75. Lycke N, Holmgren J. 1986. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59:301-308.
76. Bromander AJ, Holmgren J, Lycke N. 1991. Cholera toxin stimulates IL-1 production and enhances antigen presentation by macrophages in vitro. J Immunol 146:2908-2913.
77. Pizza M, Giuliani MM, Fontana MR, Monaci E, Douce G, et al. 2001. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 19:2534-2541.
78. Mc Cluskie MJ, Weeratna RD, Krieg AM, Davis HL. 2000. CpG DNA is an effective oral adjuvant to protein antigens in mice. Vaccine 19:950-957.
79. Aizpurua DeHJ, Russel-Jones GJ. 1988. Oral vaccination. Identification of classes of proteins that provoke an immune response upon oral feeding. J Exp Med 167:440-451.
80. Hilgers LAT, Ghenne L, Nicolas I, Fochesato M, Lejeune G, et al. 2000. Alkyl-polyacrylate esters are strong mucosal adjuvants. Vaccine 18:3319-3325.
81. Smith RE, Donachie AM, Mowat AM. 1998. Immune stimulating complexes as mucosal vaccines. Immunol Cell Biol 76:263-269.
82. Karlsen TH, Sommerfelt H, Klomstad S, Andersen PK, Strand TA, et al. 2003. Intestinal and systemic immune responses to an oral cholera toxoid B subunit whole-cell vaccine administered during zinc supplementation. Infec Immun 71:3909-3913.
83. Belyakov IM, Derby MA, Ahlers JD, Kelsall BL, Earl P, et al. 1998. Mucosal immunization with HIV-1 peptide vaccine induces mucosal and systemic cytotoxic T lymphocytes and protective immunity in mice against intrarectal recombinant HIV-vaccinia challenge. Proc Nat Acad Sci USA 95:1709-1714.
84. + Cytotoxic T Lymphocytes for Resistance to Mucosal Viral Transmission in Mice and Enhancement of Resistance by Local Administration of IL-12. J Clin Invest 102:2072-2081.
85. Zhao X, Zhang M, Li Z, Frankel FR. 2006. Vaginal protection and immunity after oral immunization of mice with a novel vaccine strain of Listeria monocytogenes expressing human immunodeficiency virus type 1 gag. J Virol 80:8880-8890.
86. Kawahara M, Hashimoto A, Toida I, Honda M. 2002. Oral recombinant Mycobacterium bovis bacillus Calmette-Guarin expressing HIV-1 antigens as a freeze dried vaccine induces long-term, HIV-specific mucosal and systemic immunity. Clin Immunol 105:326-331.
87. Xin KQ, Hoshino Y, Toda Y, Igimi S, Kojima Y, et al. 2003. Immunogenicity and protective efficacy of orally administered recombinant Lactococcus lactis expressing surface-bound HIV Env. Blood 102:223-228.
88. Karpenko LI, Nekrasova NA, Ignat'ev GM, Agafonov AP, Proniaeva TP, et al. 2003. Immune response in oral and rectal immunization by the attenuated strain of salmonella carrying the HIV DNA-vaccine. Vopr Virusol 48:16-20.
89. Horn ME, Pappu KM, Bailey MR, Clough RC, Barker M, et al. 2003. Advantageous features of plant-based systems for the development of HIV vaccines. Journal of Drug Target 11:539-545.
90. Zhang H, Huang Y, Fayad R, Spear GT, Qiao L. 2004. Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles. J Virol 78: 8342-8348.
91. Gupta P, Waheed SM, Bhatnagar R. 1999. Expression and purification of the recombinant protective antigen of Bacillus anthracis. Protein Expr Purif 16:369-376.
92. Aloni-Grinstein R, Gat O, Altboum Z, Velan B, Cohen S, et al. 2005. Oral spore vaccine based on live attenuated nontoxinogenic Bacillus anthracis expressing recombinant mutant protective antigen. Infect Immun 73:4043-4053.
93. Aziz MA, Sikriwal D, Singh S, Jarugula S, Kumar PA, et al. 2005. Transformation of an edible crop with the pagA gene of Bacillus anthracis. FASEB J 19:1501-1503.
94. Roden R, Wu TC. 2006. How will HPV vaccines affect cervical cancer? Nat Rev Cancer 6:753-763.
95. Busby JE, Pettaway CA. 2005. What's new in the management of penile cancer? Curr Opin Urol 15:350-357.
96. Warzecha, Mason HS, Lane C, Tryggvesson A, Rybicki E, et al. 2003. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 77:8702-8711.
97. Biernelt S, Sonnewald U, Galmbacher P, Willmitzer L, Muller M. 2003. Production of human papillomavirus type 16 virus-like particles in transgenic plants. J Virol 77:9211-9220.
98. Baud D, Ponci F, Bobst M, De Grandi P, Nardelli-Haefliger D. 2004. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol 78:12901-12909.
99. Liang W, Wang S, Yu F, Zhang L, Qi G, et al. 2003. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, I EM108. Infect Immun 71:5498-5504.
100. Eko FO, Schukovskaya T, Lotzmanova EY, Firstova VV, Emalyanova NV, et al. 2003. Evaluation of the protective efficacy of Vibrio cholerae ghost (VCG) candidate vaccines in rabbits. Vaccine 21:3663-3674.
101. Qadri F, Wenneras C, Ahmed F, Asaduzzaman M, Saha D, et al. 2003. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi children 18-36months of age. Vaccine. 21:2394-2403.
102. Liao CW, Lin SH, Lin PY, Chiou HY, Chang WF, et al. 2004. Orally administered enterotoxigenic Escherichia coli vaccine encapsulated by ethylcellulose powder dispersion. Appl Microbiol Biotechnol 65:295-300.
103. Yahong H, Liang W, Pan A, Zhou Z, Wang Q, et al. 2006. Protective immune response of bacterially-derived recombinant FaeG in piglets. J Microbiol. 44:548-555.
104. Vesikari T. 1999. Rotavirus vaccines: development and use for the prevention of diarrhoeal disease. Ann Med 31:79-85.
105. Murphy TV, Gargiullo PM, Massoudi MS, Nelson DB, Jumaan AO, et al. 2001. Intussusception among infants given an oral rotavirus vaccine. N Eng J Med 344:564-573.
106. Wu YZ, Li JT, Mou ZR, Fei L, Ni B, et al. 2003. Oral immunization with rotavirus VP7 expressed in transgenic potatoes induced high titers of mucosal neutralizing IgA. Virology 313:337-342.
107. Wigdorovitz A, Mozgovoj M, Dus Santos MJ, Parreño V, Gómez C, et al. 2004. Protective lactogenic immunity conferred by an edible peptide vaccine to bovine rotavirus produced in transgenic plants. J Gen Virol 85:1825-1832.
108. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, et al. 2006. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 354:23-33.
109. Vesikari T, Karvonen AV, Majuri J, Zeng SQ, Pang SL, et al. 2006. Safety, Efficacy, and Immunogenicity of 2 Doses of Bovine-Human (UK) and Rhesus-Rhesus-Human Rotavirus Reassortant Tetravalent Vaccines in Finnish Children. J Infect Dis 194:370-376.
110. Wang L, Kedzierski L, Wesselingh SL, Coppel RL. 2003. Oral immunization with a recombinant malaria protein induces confirmational antibodies and protects mice against lethal malaria. Infect Immunity 71:2356-2364.
111. Carcaboso AM. 2003. Immune response after oral administration of the encapsulated malaria synthetic peptide SPf 66. Int J Pharm 260:273-282.
112. Wang L, Goschnick MW, Coppel RL. 2004. Oral immunization with a combination of Plasmodium yoelii merozoite surface proteins 1 and 4/5 enhances protection against lethal malaria challenge. Infect Immun 72:6172-6175.
113. Webster DE, Cooney ML, Huang Z, Drew DR, Ramshaw IA, et al. 2002. Sucessful boosting of a DNA measles immunization with an oral plant derived measles virus vaccine. J Virol 76:7910-7912.
114. Webster DE, Thomas MCT, Strugnell RA, Dry ID, Wesselingh SW, et al. 2002. Appetising solutions: an edible vaccine for measles. Med J Aust 176:434-437.
115. Marquet-Blouin E, Bouche FB, Steinmetz A, Muller CP. 2003. Neutralizing immunogenicity of transgenic carrot (Daucus carota L.)-derived measles virus hemagglutinin. Plant Mol Biol 51:459-469.
116. Bouche FB, Marquet-Blouin E, Yanagi Y, Steinmetz A, Muller CP. 2003. Neutralising immunogenicity of a polyepitope antigen expressed in a transgenic food plant: a novel antigen to protect against measles. Vaccine 21:2065-2072.
117. Gundel I, Weidinger G, Meulen VT, Heesemann J, Rüssmannet H, et al. 2003. Oral immunization with recombinant Yersinia enterolitica expressing a measles virus CD4 T cell epitope protects against virus-induced encephalitis. J Gen Virol 84:775-779.
118. Wang-Chew RM. 2006. Immunogenicity of aerosol measles vaccine given as the primary measles immunization to nine-month-old Mexican children. Vaccine 24:683-690.
119. Coates AL, Tipples G, Leung K, Gray M, Louca E. 2006. How many infective viral particles are necessary for successful mass measles immunization by aerosol? Vaccine 24:1578-1585.
120. Calmette A, Weill-Halle B, Saenz A, Costil L. 1933. Demonstration experimentale du passage des bacille-vaccins BCG a travers Ia muquese de l'intestin chez l'enfant et chez le singe. Bull Acad Med 110:203-206. (In French.)
121. Levine MM, Ferreccio C, Abrego P, Martin OS, Ortiz E, et al. 1999. Duration of efficacy of Ty21a attenuated Salmonella typhi live oral vaccine. Vaccine 2:S22-S27.
122. Aldwell FE, Tucker IG, de Lisle GW, Buddle BM. 2003. Oral delivery of Mycobacterium bovis BCG in a lipid formulation induces resistance to pulmonary tuberculosis in mice. Infect Immun 71:101-108.
123. Cosgrove CA, Castello-Branco LR, Hussell T, Sexton A, Giemza R, et al. 2006. Boosting of cellular immunity against Mycobacterium tuberculosis and modulation of skin cytokine responses in healthy human volunteers by Mycobacterium bovis BCG substrain Moreau Riode Janeiro oral vaccine. Infect Immun 74:2449-2452.
124. Pierce N, Cray W. 1982. Determinants of the localization, magnitude, and duration of a specific mucosal IgA plasma cell response in enterically immunized mice. J Immunol 128:1311-1315.
125. Lange S, Nygren H, Svennerholm A, Holmgren J. 1980. Antitoxic cholera immunity in mice. Influence of antigen deposition on antitoxin-containing cells and protective immunity in different parts of the intestine. Infect Immunol 28:17-23.
126. Mattingly JA, Waksmann BH. 1978. Immunological suppression after oral administration of antigen. I. Specific suppressor cells formed in Peyers patches after oral administration of sheep erythrocytes and their systemic migration. J Immunol 121:1878-1883.
127. Weiner HL. 1994. Oral tolerance. Proc Natl Acad Sci USA 91:10762-10765.
128. Russell-Jones GJ. 2000. Oral vaccine delivery. J Control Release 65:49-54.